|
Outcome
|
Unadjusted analysis
|
Adjusted analysis b
|
|---|
|
Hazard ratio (95% CI)
|
P value
|
Hazard ratio (95% CI)
|
P value
|
|---|
|
PFS-1TLc
|
0.44 (0.27, 0.72)
|
< 0.01
|
0.60 (0.36, 0.98)
|
0.04
|
|
OS-1TLc
|
0.10 (0.02, 0.40)
|
< 0.01
|
0.14 (0.03, 0.59)
|
< 0.01
|
- CI Confidence interval; HR Hazard ratio; OS Overall survival; PFS Progression-free survival
- a Reference category is “not SHERBOC”
- b HRs are adjusted for age at study entry, tumor grade, Eastern Cooperative Oncology Group grading, metastasis pattern, and number of concomitant diseases
- c -1TL refers to the PFS or OS of the therapy line before a possible inclusion into the SHERBOC trial
